Prostate-specific antigen （PSA） testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, c...Prostate-specific antigen （PSA） testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determininE the need for salva=e theraov.展开更多
文摘Prostate-specific antigen （PSA） testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determininE the need for salva=e theraov.
文摘[目的]探讨前列腺癌（PCa）患者血清腺激肽释放酶2（human kallikrein 2,hK2）检测的临床意义。[方法]采用酶联免疫吸附试验（ELISA）和放射免疫分析法（RIA）分别检测30例PCa、30例前列腺增生（BPH）患者和30名健康人血清hK2和前列腺特异性抗原（PSA）的水平。并随访12例行根治性前列腺全切术后PCa患者hK2水平。[结果]PCa组hK2水平为78.8±25.2ng/L,明显高于BPH组（25.4±6.28ng/L）和健康组（24.1±4.16ng/L）,差异有统计学意义（P〈0.05）;hK2检测PCa的敏感度、特异性、准确率分别为63.3%,90.0%,76.6%;血清hK2诊断PCa的ROC曲线下面积为0.767（95%CI：0.642-0.891）;12例PCa患者手术前和手术后hK2比较差异有统计学意义（81.5±24.8ng/L vs 38.4±13.5ng/L,P〈0.001）。[结论]血清hk2诊断PCa,可能可以提高其特异性,减少不必要的活检率,有望成为新的PCa检测指标预测高危人群。
